Aiosyn, a Netherlands-based startup developing a diagnostics platform that uses AI to support pathologists with accurate and efficient clinical diagnostics, announced that it raised €2 million in a fresh round of funding.
The round was led by Utrecht-based Health Innovations along with Oost NL, an East Netherlands Development Agency, and Eindhoven-based VC firm LUMO Labs.
The funds will help the company to further develop its platform and accelerate the time to market.
Patrick de Boer, CEO, and co-founder of Aiosyn says, “Aiosyn develops algorithms that work in close synergy with pathologists to improve the digital pathology workflow and clinical diagnostic tasks. With this investment, we can accelerate our first product launch and lay the foundation for the future product roadmap.”
In 2021, Aiosyn developed two algorithms and set up its certification process. Recently, the company also received ISO 13485 certification, which is a crucial initial step in the development of high-quality AI-based medical devices.
Company: Aiosyn BV.
Raised: €2.0M
Round: Unknown
Funding Month: December 2022
Lead Investors: Health Innovations
Additional Investors: Oost NL and LUMO Labs.
Company Website: https://www.aiosyn.com/
Software Category: Diagnostics platform
About the Company: Founded in 2021 and led by CEO Patrick de Boer, Aiosyn aims to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients globally. Aiosyn's primary focus is on creating, integrating, and approving AI solutions for clinical diagnostic assistance for difficult-to-diagnose conditions, including breast and prostate cancer. The startup also provides solutions for businesses in the biotech, pharmaceutical, and diagnostics sectors who want to use AI to enhance their pathological workflows. The company is a spin-off of the Computational Pathology Group of the Radboudumc in Nijmegen, the Netherlands.
Source: https://siliconcanals.com/crowdfunding/aiosyn-bags-2m/